{"id":504642,"date":"2020-08-28T13:32:01","date_gmt":"2020-08-28T13:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=504642"},"modified":"2020-08-28T13:32:01","modified_gmt":"2020-08-28T13:32:01","slug":"spinal-muscular-atrophy-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/spinal-muscular-atrophy-pipeline-assessment-key-companies-and-emerging-drugs_504642.html","title":{"rendered":"Spinal Muscular Atrophy Pipeline Assessment, Key Companies And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Spinal Muscular Atrophy Pipeline Assessment, Key Companies And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Spinal Muscular Atrophy Pipeline Assessment, Key Companies And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Spinal Muscular Atrophy Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Spinal Muscular Atrophy market. <\/p>\n<\/div>\n<p style=\"text-align: justify;\">The&nbsp;<strong>Spinal Muscular Atrophy Pipeline report<\/strong> embraces in-depth commercial assessment and clinical assessment of the Spinal Muscular Atrophy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal Muscular Atrophy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/spinal-muscular-atrophy-sma-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/spinal-muscular-atrophy-sma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/3688a29d6742d70b2ca43d0f5f3c0593.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Spinal Muscular Atrophy pipeline possess multiple potential drugs in late and mid stage developments to be launched in the near future. Some of the key players developing therapies for the treatment of patients with Spinal Muscular Atrophy includes:<\/strong><br \/>Novartis<br \/>PTC Therapeutics <br \/>Cytokinetics<br \/>Astellas<br \/>Catalyst Pharmaceuticals <br \/>Biogen<br \/>Novartis<br \/>Hoffmann-La Roche<br \/>And many others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Drugs Covered<\/strong><br \/>Reldesemtiv (CK-2127107)<br \/>Amifampridine Phosphate (Firdapse)<br \/>BVS 857<br \/>SRK-015<br \/>Branaplam (LMI070)<br \/>And few others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-sma-pipeline-insight\" target=\"_blank\"><strong>Spinal Muscular Atrophy Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Spinal Muscular Atrophy treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Spinal Muscular Atrophy key players<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of <strong>Spinal Muscular Atrophy market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Spinal Muscular Atrophy Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Spinal Muscular Atrophy across the complete product development cycle, including all clinical and nonclinical stages.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It comprises of detailed profiles of <strong>Spinal Muscular Atrophy therapeutic products<\/strong> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed <strong>Spinal Muscular Atrophy research and development<\/strong> progress and trial details, results wherever available, are also included in the pipeline study.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage of dormant and discontinued pipeline projects along with the reasons if available across Spinal Muscular Atrophy.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Spinal Muscular Atrophy.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">In the coming years, the <strong>Spinal Muscular Atrophy market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The companies and academics that are working to assess challenges and seek opportunities that could influence <strong>Spinal Muscular Atrophy R&amp;D<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-sma-pipeline-insight\" target=\"_blank\"><strong>Spinal Muscular Atrophy treatment market<\/strong><\/a>. Several potential therapies for Spinal Muscular Atrophy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Spinal Muscular Atrophy market size in the coming years.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Our in-depth analysis of the pipeline assets (in <strong>early-stage, mid-stage and late stage of development for the treatment of Spinal Muscular Atrophy<\/strong>) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Spinal Muscular Atrophy&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Spinal Muscular Atrophy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Spinal Muscular Atrophy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Spinal Muscular Atrophy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Spinal Muscular Atrophy Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Spinal Muscular Atrophy Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Spinal Muscular Atrophy Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Spinal Muscular Atrophy Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Spinal Muscular Atrophy Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Spinal Muscular Atrophy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Spinal Muscular Atrophy Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Spinal Muscular Atrophy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-market-insights-epidemiology-and-market-forecast\">Spinal Muscular Atrophy (SMA) Market Insight, Epidemiology and Market Forecast -2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;Spinal Muscular Atrophy (SMA) Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Spinal Muscular Atrophy (SMA), historical and forecasted epidemiology as well as the Spinal Muscular Atrophy (SMA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-sma-epidemiology-forecast\">Spinal Muscular Atrophy (SMA) Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s Spinal Muscular Atrophy (SMA) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Spinal Muscular Atrophy (SMA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Anuj Rawat<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=spinal-muscular-atrophy-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=spinal-muscular-atrophy-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Spinal Muscular Atrophy Pipeline Insight, 2020&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Spinal Muscular Atrophy market. The&nbsp;Spinal Muscular Atrophy Pipeline report embraces in-depth commercial assessment and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/spinal-muscular-atrophy-pipeline-assessment-key-companies-and-emerging-drugs_504642.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-504642","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/504642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=504642"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/504642\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=504642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=504642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=504642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}